Crossmark Global Holdings, Inc. Tg Therapeutics, Inc. Transaction History
Crossmark Global Holdings, Inc.
- $6.02 Billion
- Q2 2025
A detailed history of Crossmark Global Holdings, Inc. transactions in Tg Therapeutics, Inc. stock. As of the latest transaction made, Crossmark Global Holdings, Inc. holds 7,706 shares of TGTX stock, worth $268,708. This represents 0.0% of its overall portfolio holdings.
Number of Shares
7,706
Previous 5,728
34.53%
Holding current value
$268,708
Previous $225,000
23.11%
% of portfolio
0.0%
Previous 0.0%
Shares
2 transactions
Others Institutions Holding TGTX
# of Institutions
408Shares Held
92.4MCall Options Held
2.28MPut Options Held
1.78M-
Vanguard Group Inc Valley Forge, PA15.8MShares$551 Million0.01% of portfolio
-
Black Rock Inc. New York, NY11.4MShares$397 Million0.0% of portfolio
-
State Street Corp Boston, MA7.62MShares$266 Million0.01% of portfolio
-
Geode Capital Management, LLC Boston, MA3.49MShares$122 Million0.01% of portfolio
-
Clearbridge Investments, LLC New York, NY3.05MShares$106 Million0.09% of portfolio
About TG THERAPEUTICS, INC.
- Ticker TGTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 145,274,000
- Market Cap $5.07B
- Description
- TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its therapeutic product candidates include Ublituximab, an investigational glycoengineered monoclonal antibody for the treatment of B-cell non-hod...